List view / Grid view
Biochemist and physician Professor Ivan Dikic and microbiologist Professor Volker Müller are very honoured that their pioneering research projects have been selected for this substantial financial support.
New findings could help to extend the lives of patients suffering from one of the most common types of brain tumours - low-grade glioma.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Scientists unveil the complex molecular structure that causes lethal infections by Mycobacterium tuberculosis (Mtb). Their findings might have implications for potential therapies against antibiotic-resistant tuberculosis.
Head trauma is a common injury, and according to several scientific studies, undiagnosed concussion may lead to devastating outcomes and a premature neurodegenerative condition.
The new centre will serve as one of the world’s leading institutes for conducting and coordinating research about cannabinoids, endocannabinoids and medical Cannabis. In addition, it will promote collaboration and disseminate information.
A new method could push research into developmental brain disorders an important step forward.
Scientists have established a process for identifying biomarkers for the diagnosis of different types of cancer.
Meningococcal infections are the most common cause of bacterial meningitis in the United Kingdom, a life-threatening disease that poses a continuing threat worldwide. With growing fears around the increase of antibiotic-resistant bacteria, understanding why certain strains don't respond to vaccines could prove vital in helping reduce the number of global…
In a Phase I clinical trial, heart failure patients treated with patches made from their muscle cells showed improved exercise capacity and heart function after one year. Stem cell patch-based therapy may be a viable heart failure therapy and should be validated in larger clinical trials, researchers conclude.
In a collaboration between Swedish and Italian researchers, the aim was to analyse how the brain interprets information from a virtual experience of touch, created by a finger prosthesis with artificial sensation. The result was – completely unexpectedly – a new method for measuring brain health.
Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.
